MiNK Therapeutics (NASDAQ:INKT) Posts Quarterly Earnings Results, Beats Expectations By $0.16 EPS

MiNK Therapeutics (NASDAQ:INKT) announced its quarterly earnings data on Wednesday. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.16, Zacks reports. The firm had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.07 million.

Here are the key takeaways from MiNK Therapeutics’ conference call:

• MiNK has initiated a randomized Phase II ARDS trial enrolling 90 patients, comparing agenT-797 plus standard care with placebo plus standard care. The company says the protocol could transition seamlessly to Phase III, with preliminary data targeted for the second half of 2026; endpoints include survival and ventilator-free days.
• Management highlighted Phase II gastric cancer results in which median overall survival exceeded 23 months in an immune-primed cohort, with some patients still alive years after treatment. These are company-cited observations from a heavily pretreated population, and follow-up is ongoing.
• MiNK reported that the same agenT-797 product showed different immune activity in cancer and ARDS patient analyses, and said it is evaluating biomarkers that may help identify patients most likely to respond. The findings are early translational evidence, not proof of clinical benefit in the randomized trial.
• MiNK ended the first quarter with approximately $9.5 million in cash, after repaying about $5.2 million of debt and raising roughly $3 million through an at-the-market offering. Management expects at least 12 months of runway, including the ARDS trial, while the cash balance and ATM financing indicate continued funding needs may remain relevant.

MiNK Therapeutics Stock Performance

Shares of INKT stock opened at $10.22 on Thursday. MiNK Therapeutics has a 1 year low of $8.48 and a 1 year high of $16.93. The firm has a market capitalization of $52.15 million, a PE ratio of -4.26 and a beta of 0.49. The stock has a fifty day moving average of $11.17 and a two-hundred day moving average of $11.23.

Analyst Upgrades and Downgrades

Several research firms have weighed in on INKT. HC Wainwright began coverage on shares of MiNK Therapeutics in a research note on Wednesday, November 4th. They set a “buy” rating and a $38.00 target price for the company. B. Riley Financial reissued a “buy” rating and set a $50.00 target price (up from $43.00) on shares of MiNK Therapeutics in a report on Wednesday, October 21st. Zacks Research downgraded shares of MiNK Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 12th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MiNK Therapeutics in a report on Friday, October 2nd. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $44.00.

Insider Activity at MiNK Therapeutics

In other news, CEO Jennifer Buell sold 6,938 shares of the firm’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $10.56, for a total transaction of $73,265.28. Following the transaction, the chief executive officer directly owned 74,195 shares of the company’s stock, valued at approximately $783,499.20. This trade represents a 8.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 20.40% of the company’s stock.

About MiNK Therapeutics

MiNK Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell therapies for cancer. The company’s platform is based on invariant natural killer T (iNKT) cells, an immune-cell type that can recognize cancer-related targets and help stimulate broader anti-tumor immune responses. MiNK’s lead product candidate, agenT-797, is an allogeneic, or donor-derived, iNKT cell therapy designed to be developed as an off-the-shelf treatment. The candidate is being evaluated for use in oncology, including in combination with other cancer treatments such as immune checkpoint inhibitors.